Peroxisome proliferator-activated receptor gamma (PPARc), a ligand-regulated nuclear hormone receptor, plays critical roles in metabolism and adipogenesis. PPARc ligands such as thiazolidinediones (TZDs) exert insulin sensitizing and anti-inflammatory effects primarily through action on adipocytes, and are thus widely used to treat metabolic syndrome, especially type II diabetes. A number of PPARc interacting partners have been identified, many of which are known epigenetic regulators, including enzymes for histone acetylation/deacetylation and histone methylation/demethylation. However, their functional roles in the PPARc transcriptional pathway are not well defined. Recent advances in ChIP-based and deep sequencing technology are revealing previously underappreciated epigenomic mechanisms and therapeutic potentials of this nuclear receptor pathway.
Introduction
PPARc, a member of the nuclear receptor superfamily, is a ligand-regulated transcription factor that is a key metabolic regulator. It forms a heterodimer with retinoid X receptors (RXRs) and binds to a specific DR-1 motif (direct hexa-nucleotide repeats, separated by a single nucleotide) of PPAR response elements (PPREs). There are two splice variants, PPARc1, which shows relatively ubiquitous expression, and PPARc2, whose expression is restricted to mature adipocytes [1] . These variants are driven by distinct promoters, but differ only in their N-terminal sequence and have similar transcriptional activities [1, 2] . It is well established that PPARc is a master regulator of adipogenesis. PPARc targets hundreds, possibly thousands, of downstream genes in adipocytes, and is the only known factor that is necessary and sufficient for induction of adipocyte differentiation [3, 4] . The PPARc2 isoform is induced earlier and more strongly than PPARc1 during adipogenesis. The receptor is also required for maintaining the proper functions of differentiated adipocytes [5, 6] . While PPARc is most highly expressed in adipocytes and adipose tissue, it is present in numerous other cell types and tissues including macrophages, osteocytes, endothelial cells and placenta. PPARc in macrophages is implicated in anti-inflammation, uptake and reverse transport of cholesterol, and subtype specification [7, 8] . The receptor was shown to drive macrophage differentiation into the alternatively activated, anti-inflammatory population (M2), rather than the classically activated, proinflammatory population (M1) [9] . PPARc influences distinct target genes in adipocytes versus macrophages, but how these different genetic networks are established is not well understood. It is likely that the network is in part established by the distinctive chromatin pattern in each cell type to produce broad patterns of eu-and hetero-chromatin. In addition, PPARc function is dependent on the availability of coregulator proteins that modify chromatin states and as a result, may differentially regulate the transcriptional activities of PPARc and its target genes.
Many known coactivators and corepressors of PPARc and other nuclear receptors have intrinsic histone modifying activities [10] . A nucleosome, the fundamental unit of chromatin structure, consists of two of each core histone, H2A, H2B, H3 and H4, and DNA wrapped around the octameric core. The H3 and H4 histones possess N-terminal tails protruding from the nucleosome, and are particularly susceptible to post-translational modifications by specific enzymes. Modifications of chromatin, such as histone acetylation, methylation and phosphorylation, are important mechanisms of epigenetic regulation. It is thought that combinations of these modifications alter the local chromatin structure or physical properties of histone tails, which can facilitate or block the transcriptional machinery to bind to the promoter and initiate its activities. Whereas histone acetylation and phosphorylation may use charge neutralization to affect chromatin structure, this may not 0014 be true for other modifications. Furthermore, it is also likely that some of the modifications are merely a read-out of activities rather than a primary mediator. In addition, it was demonstrated that a number of these enzymes can modify not only histones but nonhistone proteins to influence transcription [10] . Furthermore, direct methylation of DNA, usually at CpG dinucleotides, and transcriptional modulation by small non-coding RNA are often considered additional epigenetic mechanisms. Epigenetic enzymes that are known to play pivotal transcriptional roles include histone methyltransferases (HMTs), histone demethylases (HDMs), histone acetyltransferases (HATs), histone deacetylases (HDACs), DNA methyltransferases and DNA demethylases. For example, di-and tri-methylation of lysine 9 or 27 of H3 (designated H3K9me2, H3K9me3, H3K27me2 or H3K27me3) are considered repressive chromatin marks, whereas mono-methylation of either lysine of H3 or lysine 20 of H4 (H3K9me1, H3K27me1, or H4K20me1) and acetylation of lysine 9 (H3K9ac) are marks of active chromatin [10, 11] . Histone acetylation exemplified by H3K9ac facilitates the access of RNA polymerase II to promoter regions just upstream of transcriptional start sites and thus stimulates transcription [11] . It is reasonably expected that like other transcription factors, epigenetic regulators underlie many activities of the nuclear receptor superfamily including PPARc. Therefore, studying epigenetic control by PPARc is key to understanding ligand-mediated transcriptional regulation of metabolic pathways. However, few studies have investigated the specific contribution and association of epigenetics changes that might be directed by this receptor. Recent technical advances involving chromatin immunoprecipitation (ChIP) such as ChIP-chip, ChIP-PET and ChIP-Seq now make it possible to uncover potential epigenomic processes that regulate or are regulated by PPARc under different conditions. Here we review the current understanding of PPARc biology in the context of epigenetics and present its perspectives in novel therapeutic approaches against metabolic disorders.
PPARc in metabolic diseases
Thiazolidinediones (TZDs), a class of drugs that act as insulin sensitizers, are high affinity ligands for PPARc [12] . Rosiglitazone and pioglitazone, are the most common anti-diabetic TZDs used clinically. While systemic, TZD treatment is effective in reducing circulating glucose, insulin, triglyceride and free fatty acid levels in diabetic subjects, although the molecular basis of this effect is incompletely understood [13] . In order to gain insight into the site and mechanism of action of the insulin-sensitizing pathway, various tissue-specific knockout models of PPARc were created, overcoming the obstacle of embryonic lethality in the whole body knockouts [3] . Major tissues or cell types that affect systemic glucose homeostasis include pancreas (e.g. b cells), muscle, liver (hepatocytes) and adipose tissue (adipocytes and macrophages). Deletion of PPARc in adipose tissue leads to insulin resistance in mice fed a high fat diet [14, 15] . On the other hand, muscle-specific PPARc knockout mice develop insulin resistance under a normal chow diet [16, 17] . Macrophage-restricted deletion of PPARc also results in systemic insulin resistance and glucose intolerance [9, 18] . In contrast, absence of PPARc in hepatocytes or b cells confers only mild effects on whole body glucose metabolism [19, 20] . While these studies suggested that adipose and non-adipose PPARc contribute to insulin resistance, it remains unclear how and where TZDs act as insulin sensitizers in the diabetic condition. Pparg expression in non-adipose tissues is generally very low. It was reported, however, that when adipose PPARc is deleted, compensation occurs by increased gene expression in muscle and liver, further complicating the use of tissue-specific knockouts to delineate the site of the TZD action [21, 22] . To avoid these complications, we created gain-of-function PPARc models where the receptor is constitutively activated through the fusion of a VP16 transactivation domain controlled by tissue-specific promoters [6] . These animals allowed us to study the contribution of PPARc in individual tissues or cell types under diet-induced insulin resistant states. Unexpectedly, we found that selective activation of PPARc in adipocytes is sufficient to improve whole body insulin resistance to a degree similar to systemic TZD treatment. Adipocyte-specific PPARc activation leads to improved adipokine and lipid profiles, lowered serum insulin levels, and suppression of macrophage inflammatory responses in a paracrine manner. These results support an ''adipocentric'' model in which adipose activation of PPARc accounts for the systemic insulin sensitizing effect of TZDs in the diabetic state. Consistent with this idea, the non-TZD compound AG035029 exhibits more adipose-selective and greater insulin sensitizing effects on Zucker fatty rats than any other drugs tested, including TZDs such as pioglitazone, rosiglitazone and troglitazone [6] . TZDs are known to have adverse side effects of osteoporosis, edema and heart failure, presumably by activating PPARc in other cell types such as osteoclasts, collecting duct cells and cardiomyocytes, respectively [23] [24] [25] [26] . By developing fat-specific PPARc modulators, it should be possible to lower the risk of side effects while achieving maximum efficacy in diabetic therapy.
Transcriptional mechanisms of PPARc in adipocytes and macrophages
PPARc binds to PPREs of its target gene promoters as a heterodimer with RXR. It is generally believed that in the absence of ligands, PPARc associates with corepressor proteins including SMRT and NCoR on PPREs. When agonists bind the receptor, these corepressors are dissociated from the complex, and coactivator proteins such as p300/CREB-binding protein (CBP) and SRC/p160 family proteins are recruited to the PPARc complex, resulting in transcriptional activation. It was reported that this exchange of corepressors and coactivators is mediated by TBL1 (transducin blike 1) and the related protein TBLR1 [27] . This suggests that the transcriptional activities of PPARc are dynamic, yet highly coordinated processes. However, the repertoire of its interacting partners can be significantly different from one cell type to another or from one gene locus to another.
Pparg expression is high in adipocytes from both white adipose tissue (WAT) and brown adipose tissue (BAT). White adipocytes store energy primarily in the form of triglycerides and cholesterol esters in a morphologically large lipid droplet, whereas brown adipocytes contain abundant mitochondria, have more lobular fat droplets and are specialized in burning energy. While PPARc is critical in the development of both WAT and BAT in vivo [5, 14] , many of its target genes are distinct at least in part due to the presence of different sets of interacting coregulators. Before full adipogenesis takes place in white adipocytes, corepressors such as NCoR and SMRT are associated through their receptor-interacting domains on PPARc2 and other specific target gene promoters and maintain the repressive states of adipogenic genes [28, 29] . In addition, it was reported that PPARc forms a repressive complex that contains the retinoblastoma protein (pRb) and histone deacetylase HDAC3 [30] . As HDAC3 is found in the complex with NCoR and SMRT [31] , the authors speculated that the presence of these corepressors facilitates pRb/HDAC3's repressive activity, although this hypothesis was not tested. Other corepressor proteins that are reported to interact with PPARc and have repressive roles in adipocytes are RIP140, SIRT1, TRB3 and TAZ ( Fig. 1 ) [32] . During differentiation into white adipocytes, phosphorylation of pRb dislodges the pRb-HDAC3 repressive complex from the receptor [28] . This may allow coactivator proteins such as p300/CBP to associate with PPARc and assist with its adipogenic activity. PPARc activity also depends on components of a chromatin remodeling SWI/SNF complex, ATPase BRG1 and BAF60c subunits [33] . Other coactivators reported to be involved in PPARc-mediated adipogenesis are subunits of the Mediator complex (PBP/MED1/TRAP220 and MED14), CARM1 (coactivator-associated arginine methyltransferase 1), MEN1/Menin, CCPG (constitutive coactivator of PPARc), ASC2/PRIP/NCOA6 and PTIP ( Fig. 1) [32, 34] . In addition to PPARc, the CCAAT/enhancer binding protein (C/EBP) family of transcription factors play an important role in adipogenesis. At the initial phase of differentiation, C/EBPb and C/EBPd are induced and stimulate expression of C/EBPa and PPARc. C/EBPa and PPARc then act reciprocally to induce a number of adipogenic target genes (e.g., aP2/FABP4, CD36, PEPCK, LPL, GLUT4 and adiponectin) and sustain their own expression by a positive feedback loop, resulting in terminal differentiation [13] . The majority of PPARc-binding sites have been identified near C/EBPa-binding regions [35, 36] . However, PPARc seems to be the principal driver of the adipogenic program. Thus, while overexpression of PPARc can induce adipogenesis in C/EBPa-deficient mouse embryonic fibroblasts (MEFs), exogenous C/EBPa expression is unable to do so in PPARc-deficient MEFs [13] . Accordingly, C/EBPa is most likely an associate factor that helps establish a poised or ''adipogenic'' state by remodeling chromatin but is dependent on PPARc to actually drive the program.
Despite its essentiality, the contribution of PPARc to brown adipocytes is less well understood. Also, C/EBPb appears to substitute for C/EBPa, though the rationale for this is also not clear [37] . A special feature of BAT is that its function of consuming or burning fat to create heat is highly conditional. Induction of PPARc coactivator-1 alpha (PGC-1a) is one key way to promote this process [38] . PGC-1a mRNA and protein levels are induced by beta-adrenergic stimulation triggered by cold exposure in BAT. In turn this increases expression of mitochondrial oxidative metabolism and adaptive thermogenic genes. One critical BAT-specific gene product that helps to generate heat is UCP-1, which is activated by PGC1a in a PPARc-dependent manner [13] . In contrast, PGC-1a does not induce the classical PPARc target aP2/Fabp4 gene, indicating gene selective coactivator functions of PGC-1a. PGC-1a also coactivates a number of other transcription factors including other nuclear receptors such as PPARa, ERRa, ERRc, ERa and ERb [13] . Another BAT-specific transcription factor PRDM16 (PR domain containing 16) was recently identified, and shown to bind PPARc in a ligand-independent manner and enhance the PPARc transcriptional activity [39] . Overexpression of PRDM16 in white preadipocytes leads to induction of some brown adipogenic programs albeit at lower levels of expression than in BAT itself. This ''browning'' may increase energy expenditure of WAT without actually converting it to BAT. Other coregulators that are suggested to contribute to brown adipogenesis are RIP140, SRC-1, lipin-1 and CtBP1/2 (C-terminal binding protein 1 and 2) [32, 40] .
The macrophage PPARc program is also distinct from both adipocyte populations. It was proposed that when TZD binds the receptor in macrophages, a small fraction of PPARc is SUMOylated, a modification that converts the RXR:PPAR heterodimer to a monomer, creating a novel interaction surface with the NCoR and SMRT corepressor complex. This SUMOylated monomer then associates, via a DNA binding independent process, to the promoters of inflammatory genes to inhibit their transcriptional activity [8, 41] . This active ''transrepression'' mechanism maintains a repressive state of inflammatory transcription in a ligand-dependent manner without involvement of classical PPREs. The SUMOylated PPARcNCoR complex has been shown to be recruited to AP1 sites through interaction with c-Jun, and represses TLR4-inducible genes. However, the extent to which ligand-dependent repression is due to this SUMOylated transrepression mechanism is not yet resolved. Furthermore, indirect mechanisms such as induction of transcriptional repressors or inhibitory micro-RNAs are likely. In regards to direct ligand dependent effects, the ChIP-based whole genome analysis shows that a majority of PPARc binding sites identified in macrophages are classical DR-1 elements and adjacent to those of C/EBPb and/or hematopoietic-specific transcription factor PU.1, as opposed to C/EBPa in adipocytes [42] . While little is known about the identity of PPARc-interacting partners associated on the DR-1 sites in this cell type, the proximity with distinct transcriptional machinery (i.e., PU.1) and possible differences in epigenetic marks may be key determinants to achieve specificity of macrophage target genes.
Genome-wide studies of PPARc in adipocytes and macrophages
Recent reports employing genome-wide ChIP analyses identified the collection of cis-acting PPARc genomic targets (termed ''cistrome'') and suggested new aspects as to how chromatin remodeling helps to direct both adipogenesis [35, 36, [43] [44] [45] [46] and macrophage activation [42] . Microarray-based platforms (ChIPon-chip [35, 44, 45] ) and direct DNA sequencing-based methods (ChIP-Seq [36, 42, 46] , ChIP-PET [43] ) have been used. As expected, after adipocyte differentiation of 3T3-L1 cell lines, the vast majority of PPARc binding sites overlap with those of its obligate heterodimer RXRa. PPARc-binding regions are enriched in acetylation of lysine 9 of H3 (H3K9ac) [35] , consistent with the idea that receptor binding correlates with active histone marks in mature adipocytes. Importantly, a significant proportion of PPARc binding regions are shared by C/EBPa binding sites (>60%), the majority of which are associated with up-regulated genes [35] . Interestingly, C/EBPb, another C/EBP family protein implicated in early adipogenesis, had a profile very similar to C/EBPa even in mature adipocytes, suggesting possible redundancy of the two isoforms. The motif analyses of surrounding sequences reveals that most of the PPARc DR-1 sites are adjacent to C/EBP binding elements [36] . This suggests that PPARc and C/EBP family proteins functionally cooperate, in the context of short distances, to induce the adipogenic transcriptional program (Fig. 1) .
More recently, Mikkelsen et al. constructed genome-wide chromatin state and PPARc localization maps during adipogenesis [46] . Using murine 3T3-L1 cells and human adipose-derived mesenchymal stem cells (ASCs) as models, they presented the extensive list of preadipocyte-and mature adipocyte-specific cis-regulatory elements. Transcriptionally active histone marks H3K4me2/me3 and H3K27ac were enriched near Ppargl and Pparg2 promoters in adipocytes from both species, while repressive H3K27me3 was not. H3K36me3, which is associated with transcriptional elongation, was increased throughout the Pparg loci during adipogenesis. PPARc-binding sites were also mapped genome-wide and localized largely to distal regions enriched for the open chromatin mark H3K27ac [46] . Although those overlapping in both models were likely to have their genes upregulated, the majority of PPARc-binding regions were not shared between 3T3-L1 and hASCs (total of approximately 7000 and 40 000 sites, respectively). It was reasoned that this discrepancy is due to genetic divergence between mouse and human. However, it is worth noting that the cell lines they used are derived from different tissues and ages. Therefore, their cell identities are likely to be different, and mechanisms of adipogenic differentiation and phenotypes of mature adipocytes may not be similar. Within adult adipose tissue, at least two populations of cell types are capable of becoming mature adipocytespreadipocytes and ASCs [47] . 3T3-L1 cells are a derivative line originally subcloned from embryonic fibroblasts. While it is not clear whether 3T3-L1 cells are identical or close to the preadipocyte lineage, this line is widely considered to be the best representative of this cell type. ASCs are multipotent and can be differentiated into mesodermal cell types, osteoblasts and chondrocytes, in addition to adipocytes, whereas preadipocytes are committed to become adipocytes. Furthermore, compared to preadipocytes, ASCs can be more effectively 'transformed' to induced pluripotent stem cells (iPSCs) by introducing pluripotency-reprogramming factors [48] . It will be of interest to study genome-wide epigenomic changes at PPARc target gene loci in adipocytes, preadipocytes, ASCs and iPSCs to delineate molecular signatures and mechanisms that correspond to cell-specific PPARc activity states.
One study investigated the cistrome of PPARc in a non-adipogenic cell type, thioglycollate-activated peritoneal macrophages, and compared these results to that found in adipocytes [42] . As was the case for adipocytes, PPARc-specific DR-1 elements are found in the majority (>75%) of identified binding sites in macrophages. Surprisingly, however, only 4% of PPARc binding regions in adipocytes are also shared in macrophages. It was demonstrated that macrophage PPARc colocalizes with PU.1, a hematopoietic transcription factor that is required for monocyte development and is not present in adipocytes. In addition, PPARc binding regions are also adjacent to those of C/EBPb. Whether C/EBPa also shares C/EBPb binding sites was not addressed. Macrophage-unique PPARc regions show increased repressive histone marks, H3K9me2 and H3K27me3, in adipocytes. In contrast, these regions exhibit open chromatin states and increased active histone mark H3K9ac in macrophages [42] . These data implicate that cell type specificity of cistromes is achieved by unique transcriptional components and distinct epigenetic regulation. Collectively, ChIPbased cistromic studies revealed that proximity of PPARc binding sites to C/EBP and PU.1 response elements helps to establish the macrophage specific PPARc response network. However, many questions remain such as, what other proteins including coactivators, corepressors and transcription factors are involved in determining cellular specificity in addition to C/EBPs and PU.1? How do epigenetic changes and chromatin remodeling contribute to the transcriptional activities of PPARc in adipogenesis and inflammation? The effect of PPARc ligands on the unliganded cistromes in adipocytes and macrophages is also not clear. More extensive cistromic analyses investigating other proteins and enzymes are likely to answer some of these questions.
Potential epigenetic players in PPARc signaling
Specific chromatin and DNA modifications that affect the PPARc transcriptional pathway are considered in detail below. The histone modifying enzymes and their possible functions described in the text are listed in Table 1 .
Histone acetyltransferases (HATs)
While we have limited knowledge about the effect of histone acetylation and deacetylation on PPARc transcriptional activity, several relevant enzymes are reported to regulate this pathway. Two classes of common PPARc interacting coactivators, SRC/p160 family proteins and p300/CBP, are known to possess intrinsic HAT activities. SRC family coactivators shown to interact with PPARc are SRC-1, GRIP1/TIF2 (SRC-2) and ACTR/AIB1 (SRC-3). While in vitro differentiation experiments point to important contributions for each SRC in adipogenesis, studies using knockout mice suggest much wider roles of each isoform in controlling energy balance between BAT and WAT in vivo [49] [50] [51] . Upon ligand binding, PPARc undergoes conformational changes which provide a contact site for LXXLL motifs in p300/CBP and SRC-1 and other co-activators, through 'charge clamp' in its ligand binding domain (LBD) [52] . In addition to ligand induced binding, p300/CBP proteins can interact with the N-terminal AF-1 domain of PPARc in a ligand-independent fashion [53] . Homozygous deletion of either p300 or CBP is embryonic lethal. Although p300 and CBP are indispensable for adipogenesis in vitro, their roles in vivo are not clear. Studies in CBP heterozygotes imply a WAT-specific function of CBP as this tissue shows significant reduction in weight in these animals [54] . Very recently, it was found that at the initial stage of adipogenesis another nuclear receptor, glucocorticoid receptor (GR), is transiently recruited along with C/EBPb to a complex consisting of PBP/MED1/TRAP220 and p300 to enhancer regions of Pparg2 isoform [55] . In response to glucocortocoids, this results in a transient increase in H3K9 acetylation and enhances the induction of PPARc2, which becomes the principal driver of adipogenesis. Cyclin D1 was shown to physically interact with p300 where it inhibits HAT activity and thus represses PPARc activity [56] . PGC-1a activation of PPARc also enhances interactions with SRC-1 or p300/CBP both in vitro and in vivo [57] . However, how HAT activities of the SRC and p300 family proteins contribute to the PPARc transcriptional program remains obscure. It is presumed that recruitment of these proteins promotes histone acetylation near transcriptional start sites, allowing the RNA polymerase to initiate transcription. As was described earlier, increased H3K9ac marks were found to increase at PPARc binding sites during adipogenesis [35, 58] . It would be important to test if the enzymatic activities of SRC or p300 coactivators are correlated with histone acetylation. Other acetylation-dependent mechanisms are also possible. One possibility is that SRC or p300 family members can directly acetylate other interacting proteins in a complex or even PPARc itself. Such non-histone acetylation may induce their conformational changes and alter protein functions, as was demonstrated for other nuclear receptor pathways. For instance, it was shown that p300 is capable of acetylating androgen receptor (AR) and estrogen receptor alpha (ERa), to control both transcriptional activity and ligand sensitivity [59, 60] .
Histone deacetylases (HDACs)
In contrast to the gene activating functions of HATs, HDACs are known to repress gene expression by deacetylating histones and condensing chromatin, thereby making the regions inaccessible to the transcriptional machinery. The 18 known human HDACs are classified by sequence and domain organization into four classes, class I (HDAC1, -2, -3 and -8), class IIa (HDAC4, -5, -7 and -9), class IIb (HDAC6 and -10), class III (sirtuin family including SIRT1 through -7) and class IV (HDAC11). Various HDAC inhibitors are effective in causing cell cycle arrest, differentiation and apoptosis of tumor cells in vivo, and thus considered promising candidates for cancer therapy [61] . Several HDACs, notably HDAC1, -2, -3 and -5, are significantly downregulated during adipogenesis in vitro [62] . However, there are conflicting results regarding the effects of knocking down HDACs on adipogenesis [62, 63] . For example, treatment with HDAC inhibitors such as valproic acid and trichostatin A, reduces PPARc levels and blocks adipogenesis in 3T3-L1 cells [64] . Cyclin D1 inhibits PPARc-dependent transcription and adipogenesis. It was reported that cyclin D1 recruits HDAC1, HDAC3 and histone methyltransferase SUV39H1 to PPREs, decreases total H3 or H3K9 acetylation, and thus inhibits the PPARc activity [65] . As described above, HDAC3 associates with pRb as a PPARc repressive complex, leading to inhibition of adipocyte differentiation, which is reversed by phosphorylation of pRb [30] . TNFa also is known to block PPARc function. It appears that IjBa-dependent nuclear translocation of HDAC3 accounts for the inhibitory action of TNFa [66] . In addition, HDAC3 mediates the transrepression mechanism of PPARc in macrophages by associating with the NCoR complex on inflammatory gene promoters in a SUMOylation-dependent manner as discussed above [41] . Adipose (ADP) protein represses adipogenesis by inhibiting PPARc transcriptional activity [67] . It was found that ADP associates with histones and HDAC3, implicating a potential chromatin modification role for ADP. Consistent with this idea, inhibition of HDAC activities effectively reverses ADP-mediated blockage of adipogenesis [67] .
Among seven mammalian sirtuins, class III NAD-dependent HDACs, SIRT1 plays an essential role in stress resistance and calorie restriction-related extension of lifespan (in yeast and worms), and thus has been most extensively studied. It was reported that SIRT1 is expressed in WAT and represses Pparg [68] . SIRT1 overexpression blocks adipogenesis, whereas inhibition of the endogenous protein increases it in vitro in 3T3-L1 cells. In vivo, fasting induces SIRT1 to bind to PPARc binding sites of fat-specific genes along with corepressors NCoR and SMRT, enhancing repressive functions. As a result, SIRT1 mediates fasting-induced lipolysis of triglycerides into free fatty acids, which is compromised in heterozygous SIRT1 mutant animals [68] . It was demonstrated more recently that a subset of PPARc target genes, including Ero1-La, FGF21, SCD3 and ELOVL3, but not classical targets, such as aP2, adiponectin and C/EBPa, are repressed by SIRT1 in vitro [69] . Activation of these genes was observed by inhibition of SIRT1, to a degree similar to TZD treatment. How SIRT1 acquires binding specificity to this subgroup of PPARc targets remains to be determined.
Histone methyltransferases (HMTs)
Histone methylation on lysine or arginine residues also plays a key role in regulating transcriptional activities. In contrast to histone acetylation that is mostly indicative of activation marks, methylation marks are associated with both active and inactive transcription. Modifications at specific residues of histones and most likely combinations of these changes determine active or repressive status of gene expression. The finding that macrophage-specific PPARc regions exhibit dramatically increased repressive marks H3K9me2 and H3K27me3 in adipocytes indicates the importance of histone methylation in achieving cell specificity of its target gene expression [42] . The best-studied HMTs for PPARc regulation are SET domain family proteins including SET-DB1 (SET domain bifurcated 1) and SETD8/PR-Set7 (PR/SET domain-containing protein 7). SETDB1 forms a corepressor complex that includes NLK (Nemo-like kinase) and represses PPARc transactivation via H3K9 methylation [45, 70] . Wnt-5a, a known inhibitory factor of adipogenesis, activates NLK, which phosphorylates SETDB1. This leads to formation of the corepressor complex and inhibits adipogenesis, which in turn promotes osteogenesis of multipotent mesenchymal stem cells [70] . ChIP-chip experiments identified significant PPARc binding to 10 of over 45 SET domain family genes [45] . Among these, SETDB1 and SETD5 are downregulated during adipogenesis, and knockdown of SETDB1 enhances differentiation of 3T3-L1 cells. In contrast, SETD8 is a direct target of PPARc, is induced during adipocyte differentiation, and its knockdown leads to inhibition of adipogenesis [45] . Importantly, SETD8 mono-methylates H4K20, and regulates PPARc-dependent activation of many target genes during adipogenesis through an increase in H4K20 monomethylation. Thus, H4K20me1 is a novel epigenetic mark for adipogenesis at least in vitro. SUV39H1 is another SET domain family protein and as described earlier, it cooperates with deacetylases, HDAC1 and HDAC3 in cyclin D1-mediated inhibition of PPARc-dependent adipogenesis, although its exact repressive function as a HMT is not clear [65] . MLL3 and MLL4, H3K4 methyltransferases, form a complex including the ASC-2/PRIP/NCOA6 protein, termed ASCOM (ASC-2 complex). ASC-2 is known to play an essential role in adipogenesis directed by PPARc. Using knockout models, both MLL3 and MLL4 proteins were demonstrated to play redundant but critical roles in PPARc-dependent adipogenesis in vitro and in vivo [71] . MLL3 and MLL4 interact with PPARc/RXRa in a TZD ligand-dependent manner, tri-methylate H3K4 at the aP2 promoter, and concomitantly increase H3 and H4 acetylation, possibly through the HAT activity of p300/CBP. PTIP (Pax transactivation domain-interacting protein) is also capable of forming a complex with ASC2-MLL3-MLL4 and modulating HMT activity. PTIP is required for expression of Pparg and Cebpa by increasing the active mark H3K4me3 on these promoters [72] . Consequently, PTIP was shown to be essential for adipogenesis both in vitro and in vivo. Other members of H3K4 methyltransferases, MLL1 and MLL2, establish an integral complex with the MEN1/menin tumor suppressor, whose human mutations are associated with various tumors including lipomas. It was demonstrated that MEN1 interacts with PPARc, enhances its target gene expression through increased H3K4 trimethylation, and is required for adiopgenesis [73] . Hepatic stellate cells (HSCs) undergo myofibroblastic transdifferentiation by suppressing the PPARc-dependent adipogenic program. Recent studies showed that methyl-CpG binding protein 2 (MeCP2) is recruited to Pparg promoter along with transcriptional repressor heterochromatin protein 1 alpha (HP1a), and increases its H3K9 methylation in HSCs [74, 75] . It is not certain which HMT is responsible for HP1a-mediated H3K9 methylation. MeCP2 also stimulates expression of HMT EZH2 and enhances H3K27 methylation in HSCs, further remodeling chromatin into the repressive structure surrounding Pparg.
In contrast to lysine methylation, very little is known about the potential role of arginine methylation in adipogenesis. Protein arginine methyltransferases (PRMTs) are comprised of 10 members (PRMT1 through -9 and FBXO11). PRMTs can methylate a diverse group of transcription factors and coregulators as well as histones [76] . PRMT4/CARM1 was originally identified as a binding partner for the p160/SRC protein GRIP1/TIF2/SRC-2 and acts as a coactivator for several nuclear receptors. In addition to H3 histone at H3R2, H3R17 and H3R26, CARM1 also methylates other coactivators, p300/CBP and SRC-3, indirectly affecting the activities of these HATs [76] . Only one study has investigated the role of PRMTs, specifically CARM1, in the PPARc pathway [77] . CARM1 was found to associate with PPARc on the aP2 promoter, and enhance transcriptional activity of the receptor in a ligand-dependent manner. CARM1 knockdown blocks adipogenesis in vitro, and CARM1-null embryos exhibit reduced BAT [77] . Although CARM1 recruitment is coincident with increased H3R17 methylation at the aP2 promoter, it is not yet clear how CARM1 augments PPARc activity and adipogenesis. For example, CARM1 has been shown to meythylate the nuclear receptor co-factor CBP and might thus act independently of histone modification. In addition to CARM1, PRMT2 was reported to interact with PPARc as well as other nuclear receptors, but its function is unknown [78] . The observation that PRMT2 coactivates the transcriptional activity of ERa predicts that this may also be the case for PPARc.
Histone demethylases (HDMs)
Direct evidence for HDMs to participate in the PPARc pathway is scarce as well. One report investigated the function of H3K9-specific HDM, JHDM2A (a.k.a. JMJD1A/KDM3A), by knocking out this protein [79] . JHDM2A is highly expressed in BAT, and animals lacking the protein have defects in b-adrenergic responses in BAT and display obesity and dyslipidemia. Upon b-adrenergic stimulation, JHDM2A is recruited along with PPARc, RXRa, PGC-1a, p300/CBP and SRC-1 to the PPRE of UCP1 gene, and reduces H3K9me2 levels at the PPRE [79] . This result unveils dynamic involvement of the HDM in a coactivator complex-mediated metabolic gene regulation. The HMT PTIP-ASC2-MLL3-MLL4 complex, which was described earlier, also contains UTX, a H3K27 demethylase, though the functional significance for its presence in the complex is unknown [72] . It is possible that many HMT complexes also possess components with counteracting HDM activities. Important roles of HDMs in other nuclear receptors have been noted. For example, LSD1/KDM1 associates with and is important for transcriptional activation of androgen receptor and ERa target genes by demethylating H3K9 [80, 81] . Similar mechanisms may exist for the PPARc cascade.
DNA methylation
DNA methylation is the only known regulatory modification of DNA itself, and involves addition of a methyl group to the carbon-5 position of cytosine typically in CpG dinucleotides. Although it is associated with gene silencing it is believed that this is dependent on the recruitment of relevant repressive complexes. DNA methylation is catalyzed by DNA methyltransferases (DNMTs). As with HDAC inhibitors, DNMT inhibitors (such as 5-aza-cytidine) have attracted great interest as epigenetic therapeutic agents for cancer [82, 83] . 5-Azacytidine is the first epigenetic drug approved by FDA and used for treatment of myelodysplastic syndrome. Combinations of HDAC and DNMT inhibitors also appear to have synergistic effects and are currently explored for treating acute myeloid leukemia and other tumors. On the other hand, the identities of DNA demethylases have been controversial, although several proteins have been proposed to possess such activities [82, 83] . There have been no studies that clearly define the molecular mechanisms of DNA methylation in Pparg regulation. In the case of the PPARc coactivator PGC-1a, it was demonstrated that DNMT3B is involved in TNFa-or free fatty acid-induced hypermethylation at non-CpG nucleotides and reduction of mitochondrial content in skeletal muscle from diabetic subjects [84] . In one study, hypomethylation of adipogenic loci including those from Pparg2, Leptin, aP2 and Lpl genes, was found in ASCs, which have a high adipogenic potential [85] . In contrast, myogenic or endothelial loci were hypermethylated in ASCs, and adipogenic loci were more methylated in non-adipogenic, hematopoietic cells. However, no change in hypomethylation was observed after adipogenesis, implying that DNA methylation serves as a molecular signature for a differentiation potential, but does not determine gene expression for driving adipogenesis [85] . Nevertheless, another study reported that the Pparg2 promoter is hypermethylated in the 3T3-L1 preadipocyte model and that upon induction of differentiation the region is gradually demethylated [86] . Methyl CpG-specific binding protein MeCP2 is associated with the promoter in preadipocytes, but is dismissed after differentiation. PPARc expression is increased in non-adipogenic NIH3T3 cells by treatment of the DNMT inhibitor, 5-aza-cytidine. Moreover, increased methylation of the Pparg2 promoter and concomitant reduction of its expression was found in visceral WAT of obese animals [86] . As described above, MeCP2 is recruited to the PPARc site, leading to HP1a-dependent H3K9 methylation and EZH2-dependent H3K27 methylation to repress its expression in HSCs [74, 75] . This result demonstrates an epigenomic relay pathway, which connects DNA methylation to histone methylation for gene regulation. Recently, it has been shown that the Tet1 (Ten-eleven translocation) protein can convert 5-methylytosine to 5-hydroxymethylcytosine (5hmc) raising the possibility that this represents a new epigenetic mark [82, 83] . More work will be necessary to explore and delineate additional roles of DNA methylation and associated enzymes in transcriptional regulations of PPARc.
Conclusion and perspectives
Despite the powerful influences on gene expression and phenotype, studies to define epigenetic molecular players and mechanisms in the PPARc signaling have just begun. Specific PPARc agonists exhibit adipogenic, lipogenic, insulin sensitizing and anti-inflammatory effects. It is thought that these properties originate from adipose tissue and account for the anti-diabetic action of the TZD compounds in insulin resistance. However, TZDs cause unwanted side effects, presumably by targeting non-adipose cell types such as cardiomyocytes, collecting duct cells and osteoclasts. Development of selective PPARc modulators or activators that are specific to adipocytes should preserve the drug efficacy while reducing side effects. Another possible means to achieve adipose selectivity could be a combination therapy of the existing TZDs with epigenetic modulators. For example, by identifying HDAC or DNMT inhibitors that are specifically effective in epigenetically activating adipogenic gene promoters, it may be possible to combine them with a lower dose of TZD yet achieve a strong anti-diabetic action. Anti-inflammatory aspects of the PPARc ligands may also offer enhanced therapeutic power of existing epigenetic drugs for cancer or inflammatory diseases when used in combination. While use of HDAC and DNMT inhibitors has been successful in cancer therapy and may be a promising target for metabolic diseases, potential mechanisms of their action in metabolic pathways are largely unknown. Identification of additional molecular factors that mediate the PPARc transcriptional pathway is likely to contribute to our understanding and designing of future therapeutic approaches in the metabolic disorders.
